The present disclosure relates to a method of treating an autoimmune condition in a patient having a genetic modification that reduces, for example, DcR3 expression, secretion, or ligand binding activity in a TNFRSF6B gene encoding a decoy receptor 3 protein (DcR3). For example, in some embodiments, the condition is a molecule that inhibits the activity of a DcR3 ligand such as LIGHT, TL1A, and FasL, such as an anti-LIGHT antibody, an anti-TL1A antibody, and an anti-FasL antibody, or non-canonical NF-κB. It can be treated with inhibitors of the pathway and the like. [Selection] Figure 1本開示は、デコイレセプター３タンパク質（ＤｃＲ３）をコードするＴＮＦＲＳＦ６Ｂ遺伝子に、例えば、ＤｃＲ３の発現、分泌、又はリガンド結合活性を低減させる遺伝子改変を有する患者において自己免疫状態を治療する方法に関する。例えば、一部の実施態様において、状態は、ＬＩＧＨＴ、ＴＬ１Ａ、及びＦａｓＬなどのＤｃＲ３リガンドの活性を阻害する分子、例えば、抗ＬＩＧＨＴ抗体、抗ＴＬ１Ａ抗体、及び抗ＦａｓＬ抗体、又は非カノニカルＮＦ－κＢ経路の阻害剤などで治療され得る。【選択図】図１
